Avantor, Inc., a global provider of products and services for the life sciences, has entered into an agreement with GeminiBio to deliver custom hydrated solutions and cell culture media to the biopharma industry.
 
Custom hydrated solutions and cell culture media are critical components of the bioproduction workflow, especially for emerging modalities such as gene therapy. The collaboration will leverage Avantor’s ability to serve manufacturing platforms with GeminiBio’s small-to-medium scale offering, enabling customers to utilize custom cGMP products through the full development lifecycle – including early-stage research, scale-up and commercialization.
 
“With the imperative to meet patient needs quickly, our customers require custom solutions to accelerate their bioproduction goals,” said Dr. Ger Brophy, Executive Vice President, Biopharma Production for Avantor. “Customized media is critical in optimizing cell line productivity, and hydrated solutions offer efficiency to biomanufacturers as they optimize their downstream processes. Our collaboration with GeminiBio will drive increases in product yields, helping bring efficiency and speed to our customers as they scale. Together, we can drive science forward to bring therapies to the patients who need them most.”
 
Brian Parker, CEO of GeminiBio said, “Enabling customers to optimize their upstream and downstream liquid manufacturing workflows by offering custom solutions, built around a strong quality foundation, has been an essential part of GeminiBio’s success. Collaborating with Avantor, who shares our focus on quality, will allow us to expand our ability to address customer needs for both small and large volume process liquids.”